La Vista, NE – Streck, Inc. and ORGENTEC SASU, a distributor in France whose specialization is in vitro diagnosis of autoimmunity, infectious diseases, molecular biology, internal/external quality control, biochemistry and sedimentation rate, have signed an exclusive distribution agreement for Streck’s cell stabilization and molecular products.
Streck’s cell stabilization products include Cell-Free DNA BCT®, a direct-draw blood collection tube which stabilizes nucleated blood cells and prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery and diagnostic assay development; Cell-Free RNA BCT®, a blood collection tube with a patented preservative which stabilizes circulating RNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage; and Cell-Free DNA Urine Preserve, a liquid reagent that stabilizes cell-free DNA in urine.
Streck’s Molecular Products division is focused on the generation of rapid diagnostic tools that impact healthcare decisions. Streck’s molecular product line includes the ARM-D® Kits for the detection of antibiotic resistance genes by multiplex real-time PCR and the upcoming rapid real-time PCR instrument, the Zulu RT™, capable of 40 cycle reactions in 20 minutes.
About ORGENTEC SASU
ORGENTEC SASU is the subsidiary of ORGENTEC GMBH in France, but has also an important activity of distribution of other laboratory reagents and automated systems in the diagnosis and research fields, including serological diagnosis of infectious diseases, molecular biology and quality controls. ORGENTEC SASU is built on the quest for excellence in their reagents, instruments, service and support offerings. The analysis of their customer’s needs, selection and mutual trust with their partners are the keys of their success.
About ORGENTEC GMBH
ORGENTEC GMBH specializes in diagnostic assays for autoimmune and infectious diseases. The company offers a portfolio of more than 300 tests, primarily enzyme-linked immunosorbent assays (ELISA), that help diagnose rheumatology, thrombosis and gastroenterology disorders, as well as infectious diseases. It also offers a fully automated instrument and associated test kits that enable laboratories to complete multiple assays and deliver faster results than traditional ELISA tests. ORGENTEC has a well-established position in Europe and a growing presence in Asia, Latin America and the Middle East.
About Streck, Inc.
Established in 1971, Streck develops and manufactures products for clinical and research laboratories. Streck’s passion for innovation, quality and service has allowed the organization to become a world leader in the development of quality control and diagnostic products that help laboratories ensure accurate and timely results for patients. Streck offers the industry’s leading automated erythrocyte sedimentation rate instrument and is a worldwide supplier of blood collection tubes that standardize methods for sample collection, stabilization and transportation. Expanding product lines include flow cytometry, body fluids and urinalysis with emerging products being developed for the burgeoning field of molecular diagnostics. For more information, visit www.streck.com.